MDM2-p53

Boehringer Launches Pivotal Trial for Liposarcoma Drug

Boehringer Ingelheim has initiated a registration trial for its investigational therapy, brigimadlin, as a potential treatment for dedifferentiated liposarcoma (DDLPS), ...